Home › Compare › VCISF vs ABBV
VCISF yields 3.78% · ABBV yields 3.06%● Live data
📍 VCISF pulled ahead of the other in Year 2
Combined, VCISF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VCISF + ABBV for your $10,000?
VINCI SA, together with its subsidiaries, operates in the concessions, energy, and construction segments primarily in France. It Concessions segment operates motorway concessions with a network of 4,419 kilometers in France; 45 airports; 4,437 kilometers of motorways; highways, railways, and 4 stadiums, as well as operates airports in France and in 11 other countries. The company's Energy segment provides services to the manufacturing, infrastructure, facilities management, and information and communication technology sectors; engineering, procurement, and construction services in the energy sector, and manufacturing and energy-related services; and renewable energy concession projects development services. Its Construction segments engages in designing and carrying out projects that involve general contractor capabilities; works related to geotechnical and structural engineering, digital technology, nuclear or renewable thermal energy; and focuses on business area, such as buildings, civil engineering, infrastructure, and in a specific geographical area. The company also provides property development services for residential and commercial properties; and property services, as well as operates managed residences. It also operates in Germany, the United Kingdom, Albania, Belarus, Bosnia-Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Kosovo, Latvia, Lithuania, Macedonia, Moldova, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, Ukraine, Portugal, North America, Central and South America, Africa, Russia, the Asia-Pacific, the Middle East, and other European countries. The company was founded in 1899 and is headquartered in Nanterre, France.
Full VCISF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.